NCT07085767Phase 3Recruiting

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2028-12Estimated
Enrollment · participants1000Estimated
Source updated2026-11-20Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Recruitment status changed

Before: Not yet recruiting. After: Recruiting.

Check registry source